Seroatlas · Human Serome Atlas

TMEM182

Transmembrane protein 182

Also known as: FLJ30294, TM182_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6ZP80
Gene: TMEM182
Ensembl: ENSG00000170417
Chromosome: 2
Canonical length: 229 aa
Protein class: Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Nucleoplasm,Vesicles

OverviewNCBI Gene

Predicted to be involved in myotube cell development involved in skeletal muscle regeneration; negative regulation of myoblast differentiation; and negative regulation of myoblast fusion. Predicted to be located in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

229 residues, UniProt reviewed canonical sequence.

>Q6ZP80|TMEM182
     1  MRLNIAIFFG ALFGALGVLL FLVAFGSDYW LLATEVGRCS GEKNIENVTF HHEGFFWRCW
    61  FNGIVEENDS NIWKFWYTNQ PPSKNCTHAY LSPYPFMRGE HNSTSYDSAV IYRGFWAVLM
   121  LLGVVAVVIA SFLIICAAPF ASHFLYKAGG GSYIAAGILF SLVVMLYVIW VQAVADMESY
   181  RNMKMKDCLD FTPSVLYGWS FFLAPAGIFF SLLAGLLFLV VGWHIQIHH

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TMEM182 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 3
Mean surface accessibility (rSASA): 0.29
Highest tissue expression: 141 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 141 nTPM
tongue: 119 nTPM
heart muscle: 91 nTPM
epididymis: 5 nTPM
prostate: 3.8 nTPM
esophagus: 3.7 nTPM

Single-cell type

cardiomyocytes: 239 nCPM
myonuclei: 234 nCPM
breast lactating cells: 140 nCPM
early spermatids: 118 nCPM
thymic myoid cells: 80 nCPM
hematopoietic stem cells: 62 nCPM

Immune cell

memory B-cell: 3.6 nTPM
MAIT T-cell: 2.9 nTPM
plasmacytoid DC: 2.9 nTPM
gdT-cell: 2.5 nTPM
naive CD4 T-cell: 2.4 nTPM
naive CD8 T-cell: 2.4 nTPM

Brain region

hypothalamus: 4.5 nTPM
pons: 4.1 nTPM
medulla oblongata: 3.7 nTPM
cerebral cortex: 3.6 nTPM
midbrain: 3.5 nTPM
white matter: 3.5 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.79
gnomAD pLI: 0.06
gnomAD missense Z: 0.09
DepMap mean gene effect: 0.04
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

muscle organ development
myotube differentiation involved in skeletal muscle regeneration
negative regulation of myoblast differentiation
negative regulation of myoblast fusion
myotube cell development involved in skeletal muscle regeneration

Cellular components

plasma membrane

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TMEM182 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

ITGB1

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TMEM182 as an antibody target. Whether an autoantibody or antibody against TMEM182 could matter depends on whether native TMEM182 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TMEM182 is annotated at the cell surface, where native TMEM182 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TMEM182 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...